Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cedric O'Gorman Insider Profile
4 Followers
Cedric O'Gorman, CMO at Relmada Therapeutics, holds 10.12K shares in Relmada Therapeutics (Ticker: RLMD). Most recently, Cedric O'Gorman Bought $10,000 shares of Relmada Therapeutics on May 24, 2023 for an estimated value of 31.80K.
Cedric O'Gorman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Cedric O'Gorman's holdings
Insider Roles
CMO
Roles that Cedric O'Gorman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Cedric O'Gorman
Cedric O'Gorman's Trading History
List of latest transactions for each holding click on a transaction to see Cedric O'Gorman's performance on stock
You May Also Like
Cedric O'Gorman insider profile FAQ
What is the percentage of profitable transactions made by Cedric O'Gorman?
The percentage of profitable transactions made by Cedric O'Gorman is ―.
What is the average return per transaction made by Cedric O'Gorman?
The average return per transaction made by Cedric O'Gorman is ―.
What stocks does Cedric O'Gorman hold?
Cedric O'Gorman holds: RLMD stocks.
What was Cedric O'Gorman’s latest transaction?
Cedric O'Gorman latest transaction was an Informative Buy of $31.80K.
What was Cedric O'Gorman's most profitable transaction?
Cedric O'Gorman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Cedric O'Gorman's role in Relmada Therapeutics?
Cedric O'Gorman's role in Relmada Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.